Clinical trials: Ejaculation
Ejaculation
Assessment Of Safety Of UK-390,957
To determine whether UK-390,957 is a safe treatment for premature ejaculation.
- Trial name
- NCT00219609
- Testing
- UK-390,957
- Where
- 82 sites in United States, Australia and 12 more
- Volunteers
- 1,058 people
- Sponsor
- Pfizer
Ejaculation
Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation
Assessment of efficacy and safety UK-390,957
- Trial name
- NCT00219635
- Testing
- UK-390,957
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 138 people
- Sponsor
- Pfizer
Erectile Dysfunction
A Study to Evaluate Intravaginal Ejaculation Time in Men With and Without Premature Ejaculation
The purpose of the study is to characterize intravaginal ejaculatory latency time (time between the start of vaginal intercourse and the start of intravaginal ejaculation) in men with and without premature ejaculation (PE) and to…
- Trial name
- NCT00210678
- Testing
- No intervention
- Volunteers
- 1,115 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Premature Ejaculation
Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation
The purpose of this study is to evaluate whether PED-1 (15mg) and PED-2 (30mg) are tolerable and effective in the treatment of premature ejaculation.
- Trial name
- NCT01203202
- Testing
- Clomipramine
- Where
- 2 sites in South Korea
- Volunteers
- 104 people
- Sponsor
- Symyoo
Premature Ejaculation
Trial of PED-1 in Male Patients With Premature Ejaculation
The purpose of this study is to evaluate whether PED-1 is more effective than Placebo in the treatment of premature ejaculation.
- Trial name
- NCT01439984
- Testing
- Clomipramine
- Where
- 5 sites in South Korea
- Volunteers
- 159 people
- Sponsor
- Symyoo
Premature Ejaculation
Study to Evaluate Efficacy and Safety in Males Subjects With Premature Ejaculation
The purpose of this clinical trial is to test an experimental drug therapy called Tramadol Hydrochloride (HCl) Orally Disintegrating Tablets (ODT) ("Tramadol HCl ODT" or the "study drug").
- Trial name
- NCT00983151
- Where
- 38 sites in Austria, Belgium and 5 more
- Volunteers
- 1,050 people
- Sponsor
- Bausch Health Americas, Inc.
Premature Ejaculation
Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation
The purpose of this clinical trial is to test an experimental drug therapy called Tramadol Hydrochloride (HCl) Orally Disintegrating Tablets (ODT) ("Tramadol HCl ODT" or the "study drug").
- Trial name
- NCT00983736
- Testing
- Tramadol Hydrochloride
- Where
- 48 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Premature Ejaculation
Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044
safety and tolerability, pharmacokinetics/efficacy of an escalating, repeat doses of YHD1044 in premature ejaculation
- Trial name
- NCT01419470
- Testing
- dapoxetine
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Yuhan Corporation
Obstetric Labour, Premature, Premature Ejaculation
A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects
PreTerm Labor (prior to 37 weeks gestation) is the largest single cause of infant morbidity and mortality and is frequently associated with long-term disability. Oxytocin is a hormone produced by the body during labor.
- Trial name
- NCT00449709
- Testing
- GSK221149
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Premature Ejaculation
A Study On Concentrations Of 16448 In Blood And The Safety Of This Compound In Healthy Males With Premature Ejaculation
16448 is being investigated for the treatment of primary premature ejaculation (PE) using a novel mode of action. There are no approved therapies for premature ejaculation, and novel therapies are needed for this syndrome.
- Trial name
- NCT00537459
- Testing
- 16448
- Where
- Ireland
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
Obstetric Labour, Premature, Premature Ejaculation
A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.
A study conducted on healthy volunteers to determine the safety, tolerability and affect on the human body by experimental drug GSK557296.
- Trial name
- NCT00549211
- Testing
- GSK557296
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sexual Dysfunction, Ejaculation
A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation
The primary purpose of the study is to assess the possible withdrawal effects after abruptly stopping daily therapy with dapoxetine compared with continuing daily therapy in men with premature ejaculation (PE).
- Trial name
- NCT00210613
- Testing
- Dapoxetine
- Volunteers
- 199 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Erectile Dysfunction
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).
- Trial name
- NCT00210704
- Testing
- Dapoxetine
- Volunteers
- 1,067 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Erectile Dysfunction
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).
- Trial name
- NCT00229073
- Testing
- dapoxetine
- Volunteers
- 1,116 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ejaculation
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.
The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).
- Trial name
- NCT00211107
- Testing
- Dapoxetine
- Volunteers
- 1,294 people
- Sponsor
- Alza Corporation, DE, USA
Ejaculation, Erectile Dysfunction
An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation
The purpose of this study is to evaluate the long-term safety of dapoxetine in men with rapid ejaculation.
- Conditions
- Ejaculation, Erectile Dysfunction, Sexual Dysfunction
- Trial name
- NCT01230762
- Testing
- dapoxetine
- Volunteers
- 1,774 people
- Sponsor
- Alza Corporation, DE, USA
Ejaculation
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).
- Trial name
- NCT00211094
- Testing
- Dapoxetine
- Volunteers
- 1,320 people
- Sponsor
- Alza Corporation, DE, USA
Premature Ejaculation
Efficacy and Safety of Paroxetine Daily Doses of 15 mg and 20 mg in the Treatment of Premature Ejaculation
As study to investigate the efficacy and safety of daily doses of paroxetine of 15 and 20 mg for the treatment of premature ejaculation
- Trial name
- NCT01024491
- Testing
- paroxetine
- Where
- 2 sites in Mexico
- Volunteers
- 174 people
- Sponsor
- MorePharma Corporation